Back to top
more

AnaptysBio (ANAB)

(Delayed Data from NSDQ)

$35.71 USD

35.71
326,963

+2.01 (5.96%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $35.72 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AnaptysBio Shares Up on Positive Top-Line Psoriasis Data

by Zacks Equity Research

AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ANAB) Outperforming Other Medical Stocks This Year?

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ANAB) Outperforming Other Medical Stocks This Year?

Will AnaptysBio Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor AnaptysBio

Is AnaptysBio (ANAB) Stock a Solid Choice Right Now?

by Zacks Equity Research

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AnaptysBio Enters Oversold Territory

by Zacks Equity Research

AnaptysBio has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -2.68% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AnaptysBio, Inc. (ANAB) Q3 Earnings Expected to Decline

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Momentum Stocks to Buy for October 31st

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 31st

AnaptysBio (ANAB) Looks Good: Stock Adds 8.1% in Session

by Zacks Equity Research

AnaptysBio (ANAB) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

    What Makes AnaptysBio, Inc. (ANAB) a New Strong Buy Stock

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

    Will AnaptysBio Continue to Surge Higher?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor in AnaptysBio.

    All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy

    by Zacks Equity Research

    AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    AnaptysBio (ANAB) Looks Good: Stock Adds 9.9% in Session

    by Zacks Equity Research

    AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

      Options Traders Expect Huge Moves in AnaptysBio (ANAB) Stock

      by Zacks Equity Research

      AnaptysBio (ANAB) needs investors to pay close attention to the stock based on moves in the options market lately.

        AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

        by Zacks Equity Research

        AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 19.72% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          Implied Volatility Surging for AnaptysBio (ANAB) Stock Options

          by Zacks Equity Research

          Investors need to pay close attention to AnaptysBio (ANAB) stock based on the movements in the options market lately.

            The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt

            by Zacks Equity Research

            The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt

              5 Best Performing IPOs of 2017

              by Zacks Equity Research

              The year 2017 marked a bounce back for the U.S. IPO market thanks to improving economy and consumer sentiment. Successful IPOs poured in primarily from the biotech and tech sectors.

                The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical

                by Zacks Equity Research

                The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical